Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Cellectis' experimental allogeneic CAR-T therapy lasme-cel receives FDA fast-track designation for treating patients wi…